Monday 9 November 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX

Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue: +41.2%
EPS: −3.67%
Free cash flow: +79.0%

Quarter to September 2026, against a year earlier

169.00 4.37 +2.65%

Follow NBIX

Alert me

Market cap: $16.7B
P/E: 24.2×
Fwd P/E: 22.5×
Dividend yield: —
F-score: 7/9
ROIC: 17.7%
Net debt / EBITDA: −2.3×
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

	Sep '26	Jun '26	Mar '26	Dec '25	Older periods
P/E ratio Full definition →	20.34	23.91	19.63	29.43	+8 more quarters Free account
P/S ratio Full definition →	3.89	5.05	4.27	4.93
P/FCF ratio Full definition →	13.86	19.56	15.93	18.85
P/Operating CF Full definition →	36.46	124.80	90.81	36.33
P/B ratio Full definition →	3.72	4.61	3.89	4.34
Price to Tangible BV Full definition →	12.14	17.60	3.90	4.35
EV/Sales Full definition →	3.84	5.09	4.02	4.61
EV/EBITDA Full definition →	14.73	20.65	15.48	20.71
EV/Operating CF Full definition →	13.35	19.14	14.45	16.85
EV/FCF Full definition →	13.68	19.74	15.01	17.61
Quick Ratio Full definition →	1.72	1.46	2.51	2.92
Current Ratio Full definition →	2.04	1.87	2.93	3.39
Net Debt/EBITDA Full definition →	(1.94)	(2.17)	(6.56)	(7.20)
Debt/Assets Full definition →	0.00%	0.00%	0.00%	0.00%
Debt/Equity Full definition →	0.00	0.00	0.00	0.00
Asset Turnover Full definition →	0.75	0.73	0.72	0.69
Operating CF/Net income Full definition →	1.91	0.94	0.74	2.53
Capex/Depreciation Full definition →	(0.24)	(0.28)	(1.25)	(0.46)
Interest Coverage Full definition →	1,104.33	52.24	—	—
Research and Development Expense of Revenue Full definition →	31.34%	34.07%	36.37%	32.05%
Selling, General and Administrative Expense of Revenue Full definition →	32.63%	45.85%	39.10%	37.47%
Intangible Assets out of Total Assets Full definition →	0.48	0.51	0.00	0.00
Share Based Compensation of Revenue Full definition →	4.84%	6.78%	7.02%	7.27%
Graham Net Nets Full definition →	0.02	0.00	0.07	0.08
Graham Number Full definition →	77.39	76.16	71.55	59.55
Earnings Yield Full definition →	4.92%	4.18%	5.09%	3.40%
Free Cash Flow Yield Full definition →	7.21%	5.11%	6.28%	5.31%
Revenue per Share Full definition →	11.05	9.50	8.10	8.10
Operating CF per Share Full definition →	3.89	1.35	1.45	3.90
Capex per Share Full definition →	(0.11)	(0.08)	(0.09)	0.02
Free Cash Flow per Share Full definition →	3.78	1.27	1.36	3.93
Cash per Share Full definition →	7.26	3.86	13.10	14.88
Shareholders Equity per Share Full definition →	38.18	36.57	33.90	32.69
Interest Debt per Share Full definition →	0.00	0.00	0.00	0.00
Book value per Share Full definition →	38.18	36.57	33.90	32.69
Free Cash Flow Full definition →	383.60	128.60	136.70	390.80
Working Capital Full definition →	1,023.60	763.00	1,604.40	1,779.30
Capital Expenditures Full definition →	(11.60)	(7.80)	(9.10)	2.40
Net Current Asset Value Full definition →	259.50	(28.00)	937.30	1,144.30
EV/EBIT Full definition →	16.04	21.62	15.82	21.30
Capex to Sales Full definition →	0.01	0.01	0.01	0.00
Price to Operating Income Full definition →	16.25	21.42	16.78	22.79
Other line items
Average Receivables Full definition →	842.65	741.35	642.05	582.95
Average Payables Full definition →	753.85	648.90	624.10	567.95
Average Inventory Full definition →	67.70	80.55	61.80	63.20
Average Assets Full definition →	4,946.55	4,624.45	4,296.95	4,175.10
Average Common Equity Full definition →	3,441.15	3,193.95	2,971.55	2,921.40

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026

Stockrow Weekly